The main ways of preventing EVA are vaccination, particularly for stallions and teasers, and the establishment of freedom from infection before breeding activities commence.
Establishing freedom from infection
This involves checking the disease status of breeding stock before commencing breeding activities each year. Veterinary surgeons should take blood samples from horses for testing in a laboratory to detect the antibodies that the horse generates in response to infection with the virus. The horse also generates antibodies in response to vaccination against EVA.
The laboratory detects both the presence and the level of antibodies in the blood ('serological testing').
If antibodies are not present ('seronegative'), the horse is not infected and breeding activities may begin.
The presence of antibodies ('seropositive') may be the result of:
In mares, a rising level of antibody in two or more sequential samples indicates active infection and the mare should not be used for breeding activity. A stable or declining level indicates previous infection or vaccination and the mare can be used safely for breeding activity.
A stallion who is shedding virus in his semen is always seropositive but a seropositive stallion is not necessarily a shedder. Therefore, if a stallion returns a seropositive result, it is important to establish whether he is a shedder (see Appendix 5) before use for breeding activities.
Routine vaccination against EVA is particularly recommended for stallions and teasers. In the UK, routine vaccination of mares is not recommended and emergency vaccination might only be considered in exceptional circumstances involving widespread disease outbreaks. One vaccine, Equip Artervac (Zoetis), is available in the UK and the last available licensed batch of this vaccine expired on 26th November 2017. Due to unforeseen circumstances, Zoetis advises that it does not expect a new batch of vaccine to be available until sometime during 2018 and a precise date cannot currently be predicted. This will result in a supply gap and there is no satisfactory alternative vaccine to source and use. Please see the box on the next page for further advice. Horses that were seronegative before vaccination will become seropositive afterwards. This positive status cannot be differentiated from positive status caused by infection. It is essential, therefore, for breeding and export purposes, to be able to demonstrate that the horse is positive because of vaccination and not infection. This is done by blood testing before vaccination to show that the horse was previously seronegative and keeping a record of the test result, certified by a veterinary surgeon, preferably in the horse’s passport. The vaccine should not be administered until the blood test result is available.
Veterinary advice should be sought on the timing and administration of the vaccine. The current datasheet requirement for the only inactivated vaccine against EVA used in Europe presently is for 6 monthly (not annual) boosters. See Appendix 8 for vaccine details.
All vaccinations (primary course and booster doses) must be recorded in the horse’s passport, by the veterinary surgeon who administered the vaccine. Details should include the date and place where the vaccine was given, and the name and batch number of the vaccine.
Advice for Owners/Agents of vaccinated stallions and teasers during the coming vaccine supply gap
The last available licensed batch of Equip Artervac vaccine expired on 26th November 2017. Due to unforeseen circumstances, Zoetis advises that it does not expect a new batch of vaccine to be available until sometime during 2018 and a precise date cannot currently be predicted. This will result in a supply gap and there is no satisfactory alternative vaccine to source and use. This will result in vaccinated stallions ‘lapsing’ six months after their last vaccination. In August 2017, the TBA advised their members to booster vaccinate or complete a primary vaccine course for any stallions or teasers that will be covering or teasing in 2018, before 26th November 2017.
Attending veterinary surgeons will need evidence to satisfy them that vaccinated stallions and teasers were seronegative before first vaccination (recorded in the horse passport) and that post-vaccination (during the ‘lapsed’ period) seropositivity is associated with vaccination and not challenge by infection, which would require notification to Defra/APHA under the terms of the Equine Viral Arteritis Order 1995. It is recommended that in addition to routine annual Code of Practice blood sampling, serial blood samples (clotted blood) are collected from vaccinated stallions and teasers during the period when Artervac vaccine is not available to provide boosters and that the separated sera from these serial blood samples are tested alongside each other once it becomes clear that Artervac will be available again. Results which show evidence of stable/declining antibody levels (titres) against the virus during the period without vaccination should be considered consistent with absence of exposure to EAV infection during that period.
For stallions and teasers last vaccinated in November 2017, the routine January 2018 blood sample should represent the approximate peak post-vaccine antibody response from which subsequent antibody levels would follow and be able to be assessed as stable or declining. It is suggested that further samples are collected at approximately 6 month intervals thereafter (so in July 2018 and then January 2019) and in that pattern until Equip Artervac is again available. When Equip Artervac is again available, a final blood sample should be taken at the same time that the stallion resumes vaccination.
In order to assist with careful collation of serum samples, the Animal Health Trust (AHT) has agreed that it will receive, process and store serial samples from stallions as part of this scheme. All samples need to be clearly labelled with the name of the stallion, the stud farm and/or owner, the date that the sample was collected and the name of the veterinary surgeon and practice that collected it. Samples should be submitted to the AHT using a special submission form specifically designed for this purpose and which can be printed as required - see http://www.aht.org.uk/cms-display/Equip_Artervac%20.html. Dates of vaccination must be recorded in horse passports.
Stallions ‘shuttling’ to the 2017/18 and 2018/19 southern hemisphere seasons may have further issues regarding ‘lapsed’ vaccinations and we recommend that involved stallion owners and managers discuss with their veterinary surgeons the specific implications on the basis of individual stallions’ circumstances. These issues may be more difficult to predict and resolve as government to government discussions may be required with individual countries involved and we cannot currently confirm if, or when, this might happen.
Recommendations for prevention - domestic mares
The risk associated with any mare can vary. Decisions regarding the testing of mares visiting stallions should therefore be made in conjunction with the attending veterinary surgeon, according to the circumstances of the individual premises and the mare's history and contacts with other horses in the past year.
In any breeding season, the safest option is to blood test all mares whether intended for natural mating or AI after 1st January and within 28 days before use for breeding activities. The mare should not be used until the results are available.
If any mare is seropositive unexpectedly, the in-contacts should be isolated and screened for EVA by blood testing. Any foster mares on the premises should also be tested.
Recommendations for prevention - imported mares
Before importing a mare, veterinary advice should be sought on the incidence of EVA in the exporting country and the following precautions taken when the disease is known or suspected to occur in that country:
Recommendations for prevention - domestic stallions
After 1st January in any year, all unvaccinated stallions and teasers should be blood tested. Do not use the stallion for breeding activities until the result is available. If the result is seronegative, breeding activities may commence.
If the result is seropositive, notify the local Field Office of the AHPA immediately and isolate the stallion while steps are taken to determine whether he is shedding the virus in his semen (see Appendix 5). He must not be used for breeding activities during this time. If he proves not to be a shedder, he may be used for breeding activities as long as any advice from the veterinary surgeon, and any conditions laid down by the RVL of the APHA, are implemented. If he proves to be a shedder, he must remain in isolation until his future is decided. None of his semen should be allowed off the premises and previously released semen should be traced and the recipients notified.
Vaccinated stallions and teasers may be seropositive or seronegative, depending on when the last dose of vaccine was given and whether the horse might have become infected since the protection afforded by the vaccine declined. These horses should be blood tested after 1st January. Do not use them for any breeding activities until the results are available. If the result is seronegative, breeding activities may begin. If it is seropositive, the stallion's history in the past 12 months - including dates of EVA vaccinations, results of pre-vaccination blood testing and any post vaccination testing and contacts with other horses since the last vaccination - should be reviewed in consultation with a veterinary surgeon.
The current datasheet requirement for the only inactivated vaccine against EVA used in Europe presently is for 6 monthly (not annual) boosters. If the EVA vaccination has lapsed or expired, the stallion may be susceptible to infection and seropositive results should be investigated. If the veterinary assessment concludes that the stallion's seropositive status is likely the result of infection rather than vaccination, isolate the stallion and notify the local Field Service Office of the Animal & Plant Health Agency (APHA). The stallion should then be tested further to determine whether he is shedding the virus in his semen (see Appendix 5). He must not be used for any breeding activities during this time.
Advice for Owners/Agents of stallions that may be exported either temporarily (shuttle) or permanently
At present, regulations regarding the export of EVA vaccinated stallions to countries outside the EU, such as Australia, are becoming stricter. AQUIS (Australian quarantine agency) require that stallions vaccinated against EVA comply with current OIE guidelines. At present these guidelines state: ‘The horse was isolated and a single blood sample taken not less than seven days after commencement of isolation and testing using a virus neutralisation test as described in the OIE Manual for equine viral arteritis with negative results. The horse was then immediately vaccinated against equine viral arteritis and remained isolated from other equids not of equivalent health status for 21 days immediately after vaccination and has been revaccinated regularly according to the manufacturer's recommendations.’
Current Artervac booster vaccinations are recommended every 6 months, which may not be compatible with stallions shuttling to Australia and other countries where Artervac does not have a current licence.
This can lead to problems with a stallion maintaining its correct vaccination history. Other countries such as New Zealand and Argentina have slightly differing import requirements at present.
Any vaccinated stallion that fails to meet import or re-import conditions may be subject to semen testing for EVA culture. It is very important to consult a veterinary surgeon as well as possible shipping agencies with regard to possible exportation of stallions to non-EU countries.
Recommendations for prevention - imported stallions
The following applies to import of stallions normally resident overseas, returning shuttle stallions and stallions who are normally resident in the UK when they have been overseas for non-breeding purposes but will be used for breeding activities upon return to this country.
Using imported stallions for breeding activities increases the risk of spread of EVA because the disease occurs worldwide and is transmitted readily between horses via the respiratory as well as the venereal route. In the UK, the law does not require any official testing of stallions for EVA before importation from EU member states so voluntary testing to establish their EVA status should be undertaken. Official testing requirements exist for imported stallions from non-EU countries. However, they may not be adequate to prevent the import of infection. Also, horses can become infected via the respiratory route during transport with other horses. Additional voluntary precautions are therefore advisable.
Before importing a stallion, veterinary advice should be taken on the incidence of EVA in the exporting country. The importer should take the following precautions when EVA is known or suspected to occur in that country:
Sport horse stallions
Where stallions are imported into the UK for competition purposes, their EVA status should be established if it is decided, after their arrival, to use them for mating or semen collection while they are in the country. The stallion should be isolated for at least 21 days, and blood tested immediately and again at least 14 days later, using the same laboratory each time. If the results are seronegative, breeding activities may commence. If any result is seropositive, notify the local Field Office of the APHA immediately, keep the stallion in isolation and consult a veterinary surgeon about the next steps. The stallion must not be used for mating, teasing or semen collection during this time.
Recommendations for prevention - artificial insemination and embryo transfer
Semen should not be used from any stallion unless that stallion has been tested for EVA according to the previous recommendations for domestic and imported stallions.
When semen is collected from a stallion:
Under EU law, import of semen from shedder stallions is not permitted.
Mare owners planning to use semen from overseas stallions should check the EVA status first. Semen should be accompanied by documentation certifying that the stallion or the semen was tested negative for EVA shortly after the semen was collected in the country of origin. Frozen semen should additionally be tested on arrival in the UK. It is only necessary to test one straw from each ejaculate. If the result is negative, the semen may be used. If it is positive, all straws from that ejaculate should be destroyed. For practical reasons it is not possible to test chilled semen on arrival. Appropriate testing in the exporting country is, therefore, essential. When transferring embryos, whether conceived in the UK or overseas, the disease status of both the stallion and mare at the time of conception must be established. Mares should have seronegative status, or seropositive status with stable or declining antibody levels. Stallions should have seronegative status, or seropositive status with proof that they are not shedders.
1. AI - see AI Guidelines
2. 'Stallion' means mating stallions, teasers and stallions used for AI.
3. Under EU law, the importation of known shedder stallions is not permitted.
4. Equine arteritis virus survives in chilled and frozen semen and is not affected by the antibiotics added.